Veterinary Monoclonal Antibodies Market
Veterinary Monoclonal Antibodies Market Size, Share, Competitive Landscape and Trend Analysis Report by Animal Type, Product Type, Indication and End User: Global Opportunity and Industry Forecast (2026-2032).
Report ID:
1153
Industry:
Healthcare
Published on:
Feb 2026
Veterinary Monoclonal Antibodies Market Summary
Global Veterinary Monoclonal Antibodies Market was a value of USD 1.70 Billion in 2025 and expected it to hit USD 3.85 Billion by 2032, with a CAGR of 12.4 % during the forecast period (2026-2032).
Veterinary Monoclonal Antibodies Industry Trends and Analytical Insights –
North America dominated the Veterinary Monoclonal Antibodies market in 2025, supported by high pet adoption rates, advanced veterinary healthcare infrastructure, strong R&D investment, and early adoption of biologic therapies for companion animals.
Companion Animals segment held the largest Veterinary Monoclonal Antibodies market share, driven by rising prevalence of chronic conditions such as osteoarthritis, dermatological disorders, and cancer, along with increased spending on premium pet healthcare.
Leading Veterinary Monoclonal Antibodies companies such as Zoetis, Elanco, Virbac, and Boehringer Ingelheim focused on biologic innovation, long-acting antibody therapies, regulatory approvals, and expansion of product pipelines targeting pain management and immune-mediated diseases.
Market Size & Forecast
Market Size 2025: USD 1.70 Billion
Projected Market Size 2032: USD 3.85 Billion
CAGR (2026-2032): 12.4%
Asia Pacific: Dominated Region of the market in 2025
Veterinary Monoclonal Antibodies Market Overview
The regulatory landscape for veterinary monoclonal antibodies is shaped by structured oversight from government agencies aimed at ensuring the safety, effectiveness, and quality of biologic therapeutics for animals. In the United States, the Animal and Plant Health Inspection Service (APHIS) under the U.S. Department of Agriculture continues to regulate veterinary biologics — including vaccines and other biological products — under the Virus-Serum-Toxin Act, processing hundreds of licensing and export certificates annually and inspecting dozens of biologics facilities each year to maintain compliance with manufacturing and safety standards. In 2024, APHIS processed 1,781 export certificates for veterinary biological products and conducted 82 facility inspections, reflecting an increase in government activity related to veterinary biologic regulation and distribution.
Concurrently, the U.S. Food and Drug Administration (FDA) has expanded approvals of monoclonal antibody therapies for companion animals, with historic authorizations such as the 2023 approval of Librela (bedinvetmab) for managing osteoarthritis pain in dogs — the first mAb approved for this indication — and an earlier approval for a similar feline pain therapy, demonstrating government recognition of targeted biologic approaches in veterinary care. Scientific literature indicates that while only a limited number of veterinary monoclonal antibody products are currently marketed compared to human therapeutics, at least five distinct mAb treatments for animals — including those for canine and feline osteoarthritis and other conditions — have received regulatory authorization in major markets, underscoring incremental progress in this therapeutic segment.
According to JBI, of adverse events associated with biologics has grown in recent years as part of regulatory oversight: the APHIS Center for Veterinary Biologics received nearly 73,000 adverse event reports in 2024, a 7 % rise from the previous year, demonstrating increased monitoring and data collection around biologics use in animal populations.
Veterinary Monoclonal Antibodies Market Dynamics
The veterinary monoclonal antibodies market is primarily driven by the growing global trend of pet ownership and the humanization of animals, which encourages increased spending on higher-quality healthcare solutions. Pet owners are more willing to seek advanced therapies that provide specific, effective, and safer treatment options for chronic and infectious diseases frequently seen in companion animals, such as atopic dermatitis, osteoarthritis, and autoimmune conditions. Technological progress in biotechnology, including advances in genetic engineering, antibody design, and AI-driven discovery, has also reduced barriers to developing species-specific mAbs with enhanced efficacy and safety profiles, accelerating development timelines and increasing commercial viability. Additionally, supportive regulatory pathways and conditional approvals from agencies like the FDA and USDA have boosted confidence among developers and practitioners, facilitating faster introductions of novel mAbs into clinical use. These drivers collectively support deeper integration of targeted biologics into routine veterinary care and broaden therapeutic choices beyond traditional small-molecule drugs.
Current trends in the veterinary monoclonal antibodies market highlight the rapid innovation and diversification of therapeutic applications. Between 2022 and 2024, more than 15 novel mAb candidates entered clinical development, with several gaining regulatory approvals, indicating an accelerated pipeline of next-generation biologics. Veterinary practices are increasingly adopting products that allow longer dosing intervals and improved patient compliance, such as shifting from monthly to quarterly dosing for pain-management antibodies, reflecting evolving clinician and owner preferences. Adoption patterns also show geographic expansion in Asia-Pacific regions such as China and India, where rising urbanization, disposable incomes, and awareness of advanced animal healthcare solutions are driving demand for targeted biologics in both companion animals and broader veterinary settings. Additionally, regulatory modernization and manufacturing enhancements are enabling cost efficiencies and higher throughput, which support broader use of monoclonal antibodies in veterinary practices worldwide.
Veterinary Monoclonal Antibodies Market Segment Analysis
Based on Animal Type, the market is segmented into Companion Animals and Livestock Animals. Companion Animals segment dominated the market in 2025 and is expected to hold the largest Veterinary Monoclonal Antibodies Market share over the forecast period. The Companion Animals segment dominates the Veterinary Monoclonal Antibodies market primarily due to the convergence of rising pet ownership, higher emotional attachment to pets, and increased willingness of owners to invest in advanced healthcare solutions. Dogs and cats account for the largest share of veterinary visits globally, and they are more frequently diagnosed with chronic, age-related, and immune-mediated conditions such as osteoarthritis, atopic dermatitis, and inflammatory pain disorders—diseases for which monoclonal antibodies offer highly targeted and long-lasting treatment benefits. Unlike traditional small-molecule drugs, monoclonal antibodies provide greater specificity with fewer systemic side effects, making them particularly suitable for long-term management in companion animals.
Veterinary Monoclonal Antibodies Market Regional Insight
North America dominated the market in 2025 and is expected to hold the largest Veterinary Monoclonal Antibodies Market share over the forecast period. North America emerged as the dominant region in the Veterinary Monoclonal Antibodies market, accounting for approximately 43–44 % of global market value, supported by advanced veterinary healthcare systems, high companion animal adoption rates, strong research and development activity, and well-established regulatory frameworks that facilitate the approval and commercialization of biologics like monoclonal antibodies. The United States, in particular, contributes significantly with a large share of companion animal households and high pet healthcare expenditure. Pet insurance coverage and the presence of leading animal health companies further reinforce North America’s leadership, driving widespread adoption of mAb therapies for chronic conditions such as osteoarthritis and atopic dermatitis in dogs and cats.
Veterinary Monoclonal Antibodies Market Competitive Landscape
The competitive landscape of the veterinary monoclonal antibodies market is characterized by a concentrated tier of large multinational animal health companies alongside emerging specialist biotech firms focusing on innovative antibody platforms. The top leaders — Zoetis Inc., Elanco Animal Health, and Merck Animal Health — collectively hold a significant portion of the global Veterinary Monoclonal Antibodies Market share and have established strong product portfolios, global distribution networks, and deep relationships with veterinarians and clinics, enabling them to maintain leadership positions.
Zoetis Inc. is often recognized as the Veterinary Monoclonal Antibodies market frontrunner, with flagship monoclonal antibody products for companion animals such as Cytopoint (Lokivetmab) for canine atopic dermatitis and Librela (bedinvetmab) for canine osteoarthritis pain; these products have driven wide clinical adoption due to proven efficacy and long dosing intervals. Elanco Animal Health is another major competitor, leveraging significant investments in biologics manufacturing and R&D — including expansion of facilities to support conditionally approved therapies such as its canine parvovirus mAb — and strengthening its pipeline for future antibody treatments.
Veterinary Monoclonal Antibodies Market Scope:
Top Veterinary Monoclonal Antibodies Market Key Players include:
Zoetis Inc.
Merck Animal Health (MSD Animal Health)
Virbac S.A.
Ceva Santé Animale
Dechra Pharmaceuticals PLC
Kindred Biosciences Inc.
Aratana Therapeutics Inc.
Indian Immunologicals Ltd.
Bayer Animal Health
Vetoquinol S.A.
PetMedix Ltd.
Nextmune
Bio-Rad Laboratories, Inc.
Creative Biolabs
GenScript Biotech Corporation
Abcam plc
Phibro Animal Health
IDEXX Laboratories Inc.
Frequently asked Questions
1. Which region dominated the Veterinary Monoclonal Antibodies market in 2025?
Ans: North America dominated the market in 2025, accounting for approximately 43–44% of global market value.
2. Why does North America lead the Veterinary Monoclonal Antibodies market?
Ans: Leadership is driven by high pet adoption rates, advanced veterinary healthcare infrastructure, strong R&D activity, favorable regulations, and high pet healthcare spending.
3. Which animal type segment dominates the Veterinary Monoclonal Antibodies market?
Ans: The Companion Animals segment dominated the Veterinary Monoclonal Antibodies market in 2025.
4. What are the key applications of veterinary monoclonal antibodies?
Ans: Major applications include pain management, dermatological disorders, oncology, and immune-mediated diseases.